People · Operator
Named in public records as an officer, director or promoter · active 2008–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
| ALDEA Pharmaceuticals, Inc. | — | Biotechnology | Series A | $27.5M | $334.9M | 2011 |
Wenjin Yang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Wenjin Yang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Wende Hutton | 1 | 16 |
| Nina Kjellson | 1 | 11 |
| Timothy Shannon | 1 | 9 |
| Howard Rosen | 1 | 5 |
| Thomas Dietz | 1 | 4 |
| Glen Sato | 1 | 4 |
| Paul Truex | 1 | 3 |
| William Yelle | 1 | 2 |
| Keith Vendola | 1 | 2 |
| Jeffrey Glenn | 1 | 2 |
| Vernon Jiang, Ph.D. | 1 | 1 |
| David Cory | 1 | 1 |
| Ed Engleman | 1 | 1 |
| Daria Mochly-Rosen | 1 | 1 |
| Richard Shames, M.D. | 1 | 1 |
| Evgeny Zaytsev | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.